-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $59

Benzinga·06/17/2026 15:02:47
Listen to the news
RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price target from $48 to $59.